ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. PhoenixBio Co's annualized net income for the quarter that ended in Mar. 2026 was 円226 Mil. PhoenixBio Co's average Total Stockholders Equity over the quarter that ended in Mar. 2026 was 円1,467 Mil. Therefore, PhoenixBio Co's annualized ROE % for the quarter that ended in Mar. 2026 was 15.39%.
The historical rank and industry rank for PhoenixBio Co's ROE % or its related term are showing as below:
TSE:6190'
s ROE % Range Over the Past 10 Years
Min: -40.37 Med: -15.59 Max: 42.12
Current: 8.74
During the past 12 years, PhoenixBio Co's highest ROE % was 42.12%. The lowest was -40.37%. And the median was -15.59%.
TSE:6190's ROE % is ranked better than 87.05% of 1251
companies
in the Biotechnology industry
Industry Median: -38.11
vs TSE:6190: 8.74
PhoenixBio Co (TSE:6190) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is two times the semi-annual (Mar. 2026) net income data. The Revenue data used here is two times the semi-annual (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
PhoenixBio Co ROE % Related Terms
PhoenixBio Co ROE % Historical Data
* Premium members only.
The historical data trend for PhoenixBio Co's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, PhoenixBio Co's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PhoenixBio Co ROE % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, PhoenixBio Co's ROE % distribution charts can be found below:
* The bar in red indicates where PhoenixBio Co's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
PhoenixBio Co (TSE:6190) has a ROE % of 15.39% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on PhoenixBio Co and its competitors. According to the industry distribution chart, PhoenixBio Co ranks #162 out of 1251 companies in the Biotechnology industry, placing it in the top 12.9%.
Is PhoenixBio Co's ROE % too high?
PhoenixBio Co's current ROE % is 15.39%. Based on the distribution chart, PhoenixBio Co ranks #162 out of 1251 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, PhoenixBio Co has a GF Score™ of 57/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does PhoenixBio Co's ROE % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, PhoenixBio Co ranks #162 out of 1251 companies for ROE %. This places PhoenixBio Co in the top 13% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Biotechnology company?
A good ROE % depends on the Biotechnology industry context. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on PhoenixBio Co and its competitors. PhoenixBio Co's current ROE % is 15.39%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PhoenixBio Co stock overvalued right now?
Based on GuruFocus' analysis, PhoenixBio Co (TSE:6190) is currently considered Fairly Valued. The stock's GF Value™ is 円361.16, compared to a current price of 円338.00 — trading 6.4% below its estimated fair value. The current ROE % is 15.39%. PhoenixBio Co's overall GF Score™ is 57/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For PhoenixBio Co (TSE:6190), the current ROE % is 15.39% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PhoenixBio Co (TSE:6190) Overvalued in 2026?
Based on GuruFocus' analysis, PhoenixBio Co stock appears to be undervalued.
The current stock price of 円338.00 is trading 6.4% below its estimated GF Value™ of 円361.16.
GuruFocus considers PhoenixBio Co to be Fairly Valued.
Key valuation signals for TSE:6190:
ROE %: 15.39%
GF Value™: 円361.16 vs. price of 円338.00 (6.4% below fair value)
No single metric tells the full story. See the TSE:6190 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PhoenixBio Co Ltd conducts study services for drug discovery and early development. It provides outsourcing services for drug development. The Company uses PXB-Mouse to conduct the study. Its services include pharmacokinetics-related tests, safety tests, and hepatitis virus (HBV / HCV) related drug efficacy tests. Geographically, the company generates the majority of its revenue from USA.
57GF Score
Get the complete analysis for TSE:6190
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:6190 has been successfully added to your 
